Bolt Biotherapeutics, Inc.
Redwood City, USA
|
Description:
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company's pipeline candidates are based on myeloid biology and cancer drug development and include BDC-1001, a HER2-targeting Boltbodyâ„¢ Immune-Stimulating Antibody Conjugate (ISAC) being evaluated in a phase 2 trial, and BDC-3042, a myeloid-modulating agonist antibody targeting Dectin-2, being evaluated in a phase 1 trial. Bolt Biotherapeutics is also developing...
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company's pipeline candidates are based on myeloid biology and cancer drug development and include BDC-1001, a HER2-targeting Boltbodyâ„¢ Immune-Stimulating Antibody Conjugate (ISAC) being evaluated in a phase 2 trial, and BDC-3042, a myeloid-modulating agonist antibody targeting Dectin-2, being evaluated in a phase 1 trial. Bolt Biotherapeutics is also developing...